scholarly journals Successful Control of Massive Bleeding in a Child with Burkitt’s Lymphoma via a Biosimilar Recombinant Activated Factor VII (AryoSeven™)

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Kourosh Goudarzi Pour ◽  
Fatemeh Malek ◽  
Peyman Eshghi
Keyword(s):  
Burkitt’S Lymphoma ◽  
Massive Bleeding ◽  
Burkitt's Lymphoma ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Present Case Report ◽  
Activated Factor Vii ◽  
Life Threatening ◽  
Massive Gastrointestinal Hemorrhage ◽  
Successful Control

We describe a case of a 4-year-old girl with Burkitt’s lymphoma, who suffered from a massive gastrointestinal hemorrhage 3 days after chemotherapy. In spite of applying the common practice in correction of coagulopathy, thrombocytopenia persisted and bleeding became life-threatening. In the present case report, we report a successful control of bleeding with a single-dose administration of a biosimilar recombinant activated human factor VII (AryoSeven).

scholarly journals Use of recombinant activated factor VII

Medicina ◽  
2009 ◽  
Vol 45 (3) ◽  
pp. 248
Author(s):  
Dagmara Reingardienė ◽  
Robertas Lažauskas
Keyword(s):  
Prothrombin Time ◽  
Liver Diseases ◽  
Hemophilia A ◽  
Tissue Injury ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Congenital Deficiency ◽  
Activated Factor Vii ◽  
Life Threatening ◽  
Hemostatic Disorders

Recombinant activated factor VII (rFVIIa) has been used in the treatment of various congenital and acquired hemostatic disorders for more than 10 years. Hemostasis is initiated by the FVIIa bound to tissue factor (TF), which constitutes only approximately 1% of total amount of the FVII protein existing in the blood. rFVII becomes activated only after the binding to the TF, released at the site of tissue injury. The efficiency of rFVIIa in the treatment of such life-threatening hemorrhagic states like hemophilia reaches up to 76–84%. rFVIIa is successfully used in the treatment of congenital deficiency of factor VII. It normalizes prothrombin time in the patients with the liver diseases and in cases of overdose of indirect anticoagulants. It is also useful for patients suffering from thrombocytopenia, thrombocyte function disorders, hemophilia A and B with development of inhibitors. rFVIIa allows overcoming uncontrollable hemorrhages, etc. It is supposed that rFVIIa is becoming a universal hemostatic drug.

Use of Recombinant Activated Factor VII in Severe Post-Partum Haemorrhage: Data From the Italian Registry. A Multicentric Observational Retrospective Study.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4434-4434
Author(s):  
Giovanni Barillari ◽  
Maria Grazia Frigo ◽  
Maddalena Casarotto ◽  
Antonio Farnia ◽  
Barbara Massè ◽  
...  
Keyword(s):  
Post Partum ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Maternal Deaths ◽  
Activated Factor Vii ◽  
Rfviia Administration ◽  
Perioperative Bleeding ◽  
Before And After ◽  
Life Threatening ◽  
Post Partum Haemorrhage

Abstract Abstract 4434 Introduction Major Post-Partum Haemorrhage (PPH) is a life-threatening labour complication, which mainly occurs without warning, predictive signs or symptoms and often in absence of predisposing conditions. Severe PPH is defined by an estimated blood loss during the first 24 hours post-partum, of more than 500mL in case of natural delivery and of more than 1000mL in case of caesarean section. In developed countries PPH incidence is reported between 0.5% and 2%. In these countries it is the third cause of maternal mortality, after venous thromboembolism (VTE) and hypertension. In developing countries, major PPH is cause of 120-000-150.000 maternal deaths every year. Therapeutic strategies for severe PPH management are largely standardized. Recombinant activated factor VII (rFVIIa) is an activated factor VII form, produced from factor VII cDNA transfected into hamster kidneys. The first case of rFVIIa administration during perioperative bleeding has been reported in 1999, since this time rFVIIa has been used as adjunctive therapy in the management of patients with life-threatening and critical haemorrhages caused by trauma, abdominal or cardiac surgery or urological surgery, liver transplantation, post partum and any other bleeding condition leading to impairment of haemostasis Purpose To report the Italian real experience in clinical practice, in order to provide wide and detailed clinical information about use of rFVIIa in the management of massive primary PPH in our country and in order to evaluate the role of haemostatic therapy in the management of this severe life- threatening obstetric complication, so contributing to treatment protocols development. Methods An Italian retrospective survey of severe primary PPH cases treated with rFVIIa was performed. Anamnestic, clinical and haemostatic data about fourty-three patients with PPH, from 2005 to 2007, were collected. Coagulative parameters and transfusion requirements before and after rFVIIa treatment were compared. Results After rFVIIa administration INR was significantly decreased, while fibrinogen levels were markedly increased. Median of packed red blood cells units, platelets units, fresh frozen plasma, crystalloids and colloids needed, before and after rFVIIa administration, were significantly decreased (tab.1). Thirty-four of 43 patients needed surgical intervention before rFVIIa administration, 11/43 after treatment. Hysterectomies have been performed respectively in 12/43 cases before and in 7/43 cases after rFVIIa infusion. The response to rFVIIa is shown in table 2 No maternal deaths have been reported. No adverse events or thromboembolic complications were observed. Conclusion rFVIIa administration represents a safe haemostatic approach in the management of severe PPH cases, when other conventional medical, surgical and radiology interventional approaches have not been successful. Data from Italian Registry, as well as from other case series, demonstrate the rFVIIa efficacy to reduce or stop obstetric critical bleeding. The use of rFVIIa as lifesaving therapy in cases, in which medical and surgical standard approach have failed, should be always considered as life well as uterus lifesaving treatment. Disclosures: Off Label Use: Safety and efficacy of rFVIIa in postpartum hemorrhage.

Recombinant Activated Factor VII Usage in Life Threatening Hemorrhage: A Pediatric Experience

2011 ◽  
Vol 78 (8) ◽  
pp. 961-968 ◽  
Author(s):  
Sunil Bhat ◽  
Satya Prakash Yadav ◽  
Madasu Anjan ◽  
Veronique Dinand ◽  
Anupam Sachdeva
Keyword(s):  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii ◽  
Life Threatening
Sign in / Sign up

Export Citation Format

Share Document